BOCCACCIO, VINCENZO
 Distribuzione geografica
Continente #
NA - Nord America 810
EU - Europa 654
AS - Asia 455
Continente sconosciuto - Info sul continente non disponibili 2
Totale 1.921
Nazione #
US - Stati Uniti d'America 796
CN - Cina 435
IE - Irlanda 205
UA - Ucraina 122
FI - Finlandia 93
DE - Germania 87
IT - Italia 54
SE - Svezia 52
GB - Regno Unito 18
CA - Canada 14
FR - Francia 10
IR - Iran 6
SG - Singapore 5
GR - Grecia 4
KR - Corea 4
CZ - Repubblica Ceca 3
IN - India 3
BE - Belgio 2
CH - Svizzera 2
EU - Europa 2
HU - Ungheria 1
LV - Lettonia 1
MY - Malesia 1
TR - Turchia 1
Totale 1.921
Città #
Dublin 205
Chandler 166
Jacksonville 158
Nanjing 122
Beijing 67
Ashburn 64
New York 62
Nanchang 47
Helsinki 34
Changsha 33
Hebei 33
Lawrence 32
Princeton 32
Wilmington 32
Medford 30
Shenyang 27
Jiaxing 25
Hangzhou 22
Tianjin 21
Boardman 18
Shanghai 16
Pavia 14
Toronto 14
Dearborn 11
Ann Arbor 6
Milan 6
Rome 6
Woodbridge 6
Kunming 5
Munich 5
Berlin 4
Chicago 4
Fairfield 4
Ningbo 4
Leawood 3
Norwalk 3
Seattle 3
Singapore 3
Verona 3
Zanjan 3
Bassano del Grappa 2
Brno 2
Des Moines 2
Jinan 2
Sacramento 2
Taizhou 2
Zhengzhou 2
Alessandria 1
Auburn Hills 1
Bolton 1
Borås 1
Brussels 1
Budapest 1
Cattolica 1
Chennai 1
Ferrara 1
Green Bay 1
Gunzenhausen 1
Henderson 1
Jinzhou 1
Kyjov 1
Lanciano 1
Lanzhou 1
Leipzig 1
Mumbai 1
New Delhi 1
Orange 1
Palermo 1
Perugia 1
Philadelphia 1
Pisa 1
Rechthalten 1
Redmond 1
Redwood City 1
Rockville 1
Shijiazhuang 1
Turin 1
Wuhan 1
Zurich 1
Totale 1.399
Nome #
Induzione e mantenimento di remissione clinica mediante l’utilizzo di Budesonide in paziente affetto da malattia di Crohn ad esordio giovanile, a localizzazione ileo-colonica e fenotipo steno-fistolizzante, già sottoposto a terapia immunosoppressiva, biologica, cellulare e chirurgica. 96
Validation and cross-cultural adaptation of the Italian translation of the Inflammatory Bowel Disease Questionnaire in patients with Crohn's disease or Ulcerative Colitis. 95
Immunosuppressive effect of bone marrow-derived mesenchymal stromal cells on gliadin-specific T cell lines 85
Phenotypical and functional characterization of bone marrow-derived mesenchymal stromal cells from patients with Crohn’s disease 81
Successful treatment of fistulizing crohn's disease with local infusions of autologous bone marrow-derived mesenchymal stem cells 75
Are anti-actin antibodies useful for coeliac disease diagnosis?. 72
Phenotypical and functional characterization of bone marrow-derived mesenchymal stromal cells from patients with Crohn’s disease 70
Study of the espression of receptor for advanced glycation end products (RAGE), in inflammatory bowel disease 69
Effects of Infliximab on circulating dendritic cell populations in Crohn’s disease 68
Herpes virus-6 chromosomal integration misled the management of Crohn’s disease 68
Interferon therapy for chronic hepatitis virus c infection is not associated to an increased risk to develop coeliac disease 67
Italian translation, cultural adaptation and initial statistical validation of the inflammatory bowel disease questionnaire 66
Bone marrow-derived mesenchymal stromal cells (MSC) locally injected for refractory fistulizing Crohn’s disease modulate immunoglobulin production 66
Validation of the Italian translation of the Inflammatory Bowel Disease Questionnaire. 61
Possible role of viral reactivations in the lack of response to conventional therapies in patients with inflammatory bowel disease (IBS) 61
Diagnostic Accuracy Of Antibodies To Deamidated Gliadin Peptides (DGP) In Coeliac Disease (CD). 57
Mucosal expression of the receptor for the advanced glycation end products (RAGE) in patients with inflammatory bowel disease (IBD) 56
Plasma levels of soluble receptor for advanced glycation end products inversely correlate with clinical and serological activity indexes in patients with Inflammatory Bowel Disease 56
Decreased Serum Levels Of Soluble Receptor For Advanced Glycation End Product (RAGE) In Patients With Inflammatory Bowel Disease (IBD) 55
Bone marrow-derived mesenchymal stromal cells locally injected for refractory fistulizing Crohn’s disease modulate serum immunoglobulins, secretory IgA, and antibody production 55
Expression Of The Soluble Form Of The Receptor For Advanced Glycation End Product (RAGE) In Patients With Inflammatory Bowel Disease (IBD) 55
Successful treatment of fistulizing crohn's disease with local infusions of autologous bone marrow-derived mesenchymal stem cells 54
In vitro characterization of bone marrow-derived mesenchymal stromal cells (MSCS) from patients with Crohn’s disease (CD) 53
The receptor for the advanced glycation end products is overexpressed in the intestinal mucosa of patients with crohn’s disease 51
Use of autologous bone marrow-derived stromal cells (MSC) transplantation as rescue therapy for adult autoimmune enteropathy 50
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 48
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 47
Immunohistochemical expression of the receptor for the advanced glycation end products (RAGE) in the intestinal mucosa of patients with Crohn’s disease (CD) 45
Decreased Serum Levels Of Soluble Receptor For Advanced Glycation End Products Inversely Correlate With Disease Activity Indexes In Patients With Inflammatory Bowel Disease 45
Reactivation of opportunistic viral infections in inflammatory bowel disease 37
Receptor for advanced glycation end products (RAGE) expression in inflammatory bowel disease (IBD) 35
Use Of Autologous Bone Marrow-Derived Mesenchymal Stromal Cells In The Treatment Of Adult Autoimmune Enterophaty. 34
Totale 1.933
Categoria #
all - tutte 6.043
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.043


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020524 126 210 4 25 2 31 5 28 2 62 29 0
2020/2021234 27 23 8 24 0 32 3 35 8 35 31 8
2021/2022136 4 0 13 0 0 1 0 11 6 2 31 68
2022/2023544 65 51 10 19 56 51 0 27 252 2 8 3
2023/2024233 40 21 3 7 22 107 1 14 3 2 8 5
2024/202514 14 0 0 0 0 0 0 0 0 0 0 0
Totale 1.933